Drugs / tremtelectogene empogeditemcel
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04849910 | Dec 2021 → May 2025 | acute myeloid leukemia, myelodysplastic syndrome | Vor Biopharma | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tremtelectogene empogeditemcel | “creating tremtelectogene empogeditemcel (trem-cel).” PMID 38027064 ↗ Oct 2023 |
| Known as | trem-cel | “creating tremtelectogene empogeditemcel (trem-cel).” PMID 38027064 ↗ Oct 2023 |
| Known as | VOR33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04849910 ↗ |
| Action | Inhibit | “we used CRISPR-Cas9 to genetically ablate the myeloid protein CD33 from healthy donor hematopoietic stem and progenitor cells (HSPCs)” PMID 38027064 ↗ Oct 2023 |
| Modality | Cell therapy | “an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product” NCT04849910 ↗ |
| Target | CD33 | “we used CRISPR-Cas9 to genetically ablate the myeloid protein CD33 from healthy donor hematopoietic stem and progenitor cells (HSPCs)” PMID 38027064 ↗ Oct 2023 |